155 related articles for article (PubMed ID: 29970541)
1.
Ferda J; Ferdová E; Baxa J; Fínek J; Topolčan O
Anticancer Res; 2018 Jul; 38(7):4139-4143. PubMed ID: 29970541
[TBL] [Abstract][Full Text] [Related]
2. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
3. Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI.
Achard V; Lamanna G; Denis A; De Perrot T; Mainta IC; Ratib O; Iselin C; Miralbell R; Garibotto V; Zilli T
Med Oncol; 2019 Jun; 36(8):67. PubMed ID: 31190232
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?
Heinisch M; Dirisamer A; Loidl W; Stoiber F; Gruy B; Haim S; Langsteger W
Mol Imaging Biol; 2006; 8(1):43-8. PubMed ID: 16315004
[TBL] [Abstract][Full Text] [Related]
5. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer.
Husarik DB; Miralbell R; Dubs M; John H; Giger OT; Gelet A; Cservenyàk T; Hany TF
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):253-63. PubMed ID: 17926036
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
8. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract][Full Text] [Related]
9. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
von Eyben FE; Kairemo K
Ann Nucl Med; 2016 Jul; 30(6):385-92. PubMed ID: 27173771
[TBL] [Abstract][Full Text] [Related]
10. The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer.
Evangelista L; Cimitan M; Hodolič M; Baseric T; Fettich J; Borsatti E
Abdom Imaging; 2015 Oct; 40(8):3230-7. PubMed ID: 26428685
[TBL] [Abstract][Full Text] [Related]
11. Value of
García JR; Compte A; Buxeda M; Mourelo S; Soler M; Blanch A; Valls E; Riera E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):197-203. PubMed ID: 32165153
[TBL] [Abstract][Full Text] [Related]
12. Long-term Results of a Comparative PET/CT and PET/MRI Study of 11C-Acetate and 18F-Fluorocholine for Restaging of Early Recurrent Prostate Cancer.
Lamanna G; Tabouret-Viaud C; Rager O; Jorcano S; Vees HJ; Seimbille Y; Zaidi H; Ratib O; Buchegger F; Miralbell R; Zilli T; Garibotto V
Clin Nucl Med; 2017 May; 42(5):e242-e246. PubMed ID: 28240662
[TBL] [Abstract][Full Text] [Related]
13.
Metser U; Berlin A; Halankar J; Murphy G; Jhaveri KS; Ghai S; Tau N
AJR Am J Roentgenol; 2018 Mar; 210(3):635-640. PubMed ID: 29323548
[TBL] [Abstract][Full Text] [Related]
14. 18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy.
Vadi SK; Singh B; Basher RK; Watts A; Sood AK; Lal A; Kakkar N; Singh SK
Clin Nucl Med; 2017 Aug; 42(8):e355-e361. PubMed ID: 28525448
[TBL] [Abstract][Full Text] [Related]
15. Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT.
Rietbergen DD; van der Hiel B; Vogel W; Stokkel MP
Nucl Med Commun; 2011 Dec; 32(12):1143-7. PubMed ID: 22045476
[TBL] [Abstract][Full Text] [Related]
16. [Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma].
Moussaid Y; Bonardel G; Jacob J; Métivier D; Gontier E; Bauduceau O; Durand X; Fayolle M; Houlgatte A; Foehrenbach H; Védrine L; Chargari C
Cancer Radiother; 2013; 17(4):259-64. PubMed ID: 23702489
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.
Kim YI; Cheon GJ; Paeng JC; Cho JY; Kwak C; Kang KW; Chung JK; Kim EE; Lee DS
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1247-56. PubMed ID: 25759164
[TBL] [Abstract][Full Text] [Related]
18. Metastatic prostate cancer proven by 18F-FCH PET/CT staging scan in patient with normal PSA but high PSA doubling time.
Hodolič M; Maffione AM; Fettich J; Gubina B; Cimitan M; Rubello D
Clin Nucl Med; 2013 Sep; 38(9):739-40. PubMed ID: 23816948
[TBL] [Abstract][Full Text] [Related]
19. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
[TBL] [Abstract][Full Text] [Related]
20. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.
Balogova S; Zakoun JB; Michaud L; Khalil A; Tassart M; Esteso A; Kerrou K; Huchet V; Carette MF; Lotz JP; Talbot JN
Clin Nucl Med; 2014 Nov; 39(11):951-9. PubMed ID: 25140552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
